Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 11, 2006, Pages 2461-2469

  Cuadrado, M J ^a   Buendia P ^b   Velasco, F ^b   Aguirre, M A ^b   Barbarroja, N ^b   Torres, L A ^b   Khamashta, M ^a   Lopez Pedrera C ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Antiphospholipid syndrome; Flt 1; Mitogen activated protein kinase signaling; Vascular endothelial growth factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DONOR; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; SIGNAL TRANSDUCTION; THROMBOSIS; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; CELLS, CULTURED; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; THROMBOPLASTIN; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33750091036     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02193.x     Document Type: Article

References (30)

1. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003; 2: 86-93.
2. Dobado-Berrios PM, López-Pedrera CH, Velasco F, Cuadrado MJ. The role of TF in the antiphospholipid syndrome. Arthritis Rheum 2001; 44: 2467-76.
3. Cuadrado MJ, López-Pedrera CH, Khamashta MA, Camps MT, Tinahones F, Torres A, Hughes GRV, Velasco F. Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte TF expression. Arthritis Rheum 1997; 40: 834-41.
4. Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the TF pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-81.
5. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS 1997; 79: 233-69.
6. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
7. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998; 83: 832-40.
8. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629-34.
9. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904-13.
10. Chen J, Bierhans A, Schiekofer S, Andrassy M, Chen B, Stem DM, Nawroth PP. Tissue factor -a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86: 334-45.
11. Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 1996; 8: 402-11.
12. Vega-Ostertag M, Kasper K, Swerlik R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545-54.
13. López-Pedrera CH, Buendía P, Cuadrado MJ, Siendones E, Aguirre MA, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta MA, Velasco F. Antiphospholipid antibodies from antiphospholipid syndrome patients induce monocyte expression through the simultaneous activation of both NF κ B/Rel proteins via p38 MAPK pathway, and the MEK1/ERK pathway. Arthritis Rheum 2006; 54: 301-11.
14. Blum S, Issbrüker K, Willuweit A, Hehlgans S, Lucerna M, Mechtcheriakova D, Walsh K, von der Ahe D, Hofer E, Clauss M. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 2001; 276: 33428-434.
15. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
16. Dobado-Berrios PM, Lopez-Pedrera CH, Velasco F, Aguirre MA, Torres A, Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82: 1578-82.
17. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995; 74: 1185-90.
18. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19: 2499.
19. Williams FMK, Parmar K, Hughes GRV, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84: 742-6.
20. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promote accumulation of ascites fluid. Science 1983; 219: 983-5.
21. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-Selectin through Nuclear Factor-kB activation in endothelial cells. J Biol Chem 2001; 276: 7614-20.
22. Freestone B, Chong AY, Lim HS, Lip GY. Angiogenic factors in atrial fibrillation: A possible role in thrombogenesis ? Ann Med 2005; 37: 365-72.
23. Dvorak HF. Angiogenesis: Update 2005. J Thromb Haemost 2005; 3: 1835-42.
24. Dupuy E, Habib A, Lebret M, Yang R, Levy-Toledano S, Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: Possible relevance to HIF-1alpha. J Thromb Haemost 2003; 1: 1096-102.
25. Hwang KK, Grossman JM, Visvanathan S, Chukwuocha RU, Woods Jr VL, Le DT, Hahn BH, Chen PP. Identification of thrombin-antithrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167: 7192-8.
26. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Haemost 2004; 30: 63-9.
27. Ohsawa M, Koyama T, Nara N, Hirosawa S. Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. Thromb Res 2003; 112: 313-20.
28. Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Garlach A. NADP oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation 2002; 105: 2030-6.
29. Itaya H, Imaizumi T, Yoshida H, Koyama M, Suzuki S, Satoh K. Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide. Thromb Haemost 2001; 85: 171-6.
30. Jung YD, Liu W, Reinmuth N, Ahmad SA, Fan F, Gallick GE, Ellis LM. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the p38 mitogen-activated protein kinase pathway. Angiogenesis 2001; 4: 155-62.